Locus Biosciences

We’re thrilled to announce we've received funding from @BARDA to advance LBP-EC01, our first-in-class #CRISPR-engineered #bacteriophage therapy, into Part 2 of our Phase 2 ELIMINATE trial for treating #UTIs caused by drug-resistant E. coli. Read more ➡️globenewswire.com/news-release/2…

With #AntibioticResistance on the rise, Locus is pioneering a new approach using bacteriophages to combat infections and other diseases like #IBD. Our AI-designed phage therapy selectively targets harmful bacteria. Read more about our efforts in @WIRED. wired.com/story/crispr-e…

Largest ever phage therapy trial shows promise for UTI treatment Urinary tract–infecting E. coli are increasingly antibiotic resistant but phage therapy offers a compelling alternative: cen.acs.org/pharmaceutical… .

🫁 𝐂𝐑𝐈𝐒𝐏𝐑-𝐞𝐝𝐢𝐭𝐞𝐝 𝐩𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐞𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐞𝐬 𝐔𝐓𝐈 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 2 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 🫁 US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of CRISPR-edited phage therapy candidate LBP-EC01. LBP-EC01 is being developed as a novel treatment for uncomplicated urinary tract infections caused by drug-resistant E. coli. The data from the trial were published in The Lancet Infectious Diseases. Read our summary of the results here: crisprmedicinenews.com/news/locus-bio… #crisprmedicinenews #crisprmedicine #crispr #phagetherapy #UTI #MDRbacteria #AMR #crisprtrial #clinicalnews #geneediting

The next phase is underway with dosing now started in the randomized, controlled, and blinded Part 2, backed by @BARDA. With 150M people affected by UTIs annually, innovative treatments like LBP-EC01 are vital. Stay tuned for more updates! #PhageTherapy eliminateuti.com

#ICYMI: Positive results from Part 1 of our Phase 2 ELIMINATE trial are published in The Lancet Infectious Diseases! LBP-EC01, our CRISPR-Cas3 engineered #bacteriophage, targets #UTIs caused by #AMR & #MDR E. coli. locus-bio.com/locus-bioscien…

Exciting news! Locus has been awarded $4.1M from @CARB_X to support the development of an engineered #bacteriophage therapy targeting infections caused by antimicrobial-resistant (#AMR) and multi-drug-resistant (#MDR) K. pneumoniae.

NCBiotech portfolio company Locus Bio has announced positive results from the first portion of its Phase 2 trial in drug-resistant UTI, affecting an estimated 150 million people worldwide. Congratulations!

Positive results from Part 1 of our Phase 2 ELIMINATE trial evaluating genetically engineered bacteriophage therapy, LBP-EC01, to treat #UTIs were published in @TheLancet Infectious Diseases. Additionally, dosing has begun in Part 2 portion of this study. globenewswire.com/news-release/2…

Check out this @TheBioBuzz article on promising new #microbiome-based approaches to medicine including #PhageTherapy. biobuzz.io/microbiome-med…

Drug-resistant infections claim ~5M lives annually. At Locus, we’re harnessing the power of #bacteriophages to target and destroy specific bacteria. Our CEO discusses our novel approach in this @voxdotcom article. vox.com/future-perfect…

Our CEO, Paul Garofolo, discussed Locus' work to revolutionize treatments for bacterial infections & other diseases like #IBD with engineered bacteriophage therapies that preserve the microbiome. Learn about our advancements in #precisionmedicine. investmentreports.co/interview/paul…

Excited for #BIO2024? Want to learn about our work to develop #precisionmedicines including bacteriophage-based therapies to combat antibiotic resistance and treat #immunology diseases including inflammatory bowel disease (#IBD)? Let’s connect. auth.inova-application.com/auth/realms/ev…

Celebrating 9 Years of Innovation and Impact! Pioneering #precisionmedicine with engineered bacteriophage therapy, combating antibiotic-resistant infections, and #immunology diseases like #IBD. Grateful for support as we continue revolutionizing treatment! #LocusTurns9

We’re excited to attend #DDW2024! As Locus develops #precisionmedicines to treat #immunology diseases including #IBD, we look forward to meeting with researchers, clinicians, and industry leaders to discuss how together we can push the boundaries of medicine.

Excited to join the @ESCMID Global Conference & CARB-X Investor Day! 🌍 As pioneers in bacteriophage-based precision medicine, Locus looks forward to insightful discussions & collaborations driving innovation in combatting antibiotic resistance. #ESCMIDGlobal #CARBX #AMR

Happy #DNADay24! We honor the discovery of DNA's double helix structure and the remarkable advancements it has led to revolutionize medicine. Locus is dedicated to pushing #biotechnology boundaries, creating a new class of bacteriophage biotherapeutics using #PrecisionMedicine.

🎉 Thrilled to announce that the Locus team exceeded our fundraising goal of $20,000 for the @CrohnsColitisFn Triangle Take Steps Walk!🚶‍♂️💙 We proudly walked in solidarity to raise #IBDAwareness. Huge thanks to all supporters!

Locus is excited to be a 2024 Triangle Take Steps event sponsor to raise #IBD awareness and support the @CrohnsColitisFn! As a Company, we're exploring how #bacteriophages and #PrecisionMedicine may help treat GI conditions including IBD. Learn more. takesteps.crohnscolitisfoundation.org/index.cfm?fuse…

Thrilled to be at the 6th Bacteriophage Therapy Summit by Hanson Wade Group today. Looking forward to dialogue around realizing the promise of #bacteriophage tx to address #AMR & other health issues. Interested in connecting? Email info@locus-bio.com. bacteriophage-summit.com

With phage therapy, researchers sharpen another arrow in the quiver against antibiotic resistance. trib.al/WGUEpR5